Search

Aim Methods Results Conclusion A study reported that therapeutic hypothermia (TH) did not reduce the combined prognosis of mortality and disability at 18 months, in low‐ and middle‐income countries for patients with hypoxic ischaemic encephalopathy (HIE) who received TH, suggesting its no implementation in these regions.We described characteristics, mortality, and neurological response before and after the use of TH in newborns with HIE within the EpicLatino Neonatal Network (ENN) and described the population of infants with HIE treated and not treated with TH.Data were collected from 2015 to 2022 for patients with HIE. Mortality rates and Sarnat scores were compared before and after TH. The Wilcoxon Signed‐Rank Test was used for comparisons.In this observational study 518 neonates of our total population of 26 970, had HIE (1.92%) of whom 150 underwent TH. Ten out of 21 neonatal intensive care units (NICUs) provided TH. The Wilcoxon Signed Rank Test for 138 cases with complete data showed a significant difference.The findings support the benefits of TH in HIE within this cohort. TH should not be withheld solely due to the economic status of the country. A strict patient selection and TH protocol are essential. [ABSTRACT FROM AUTHOR]

This article discusses the findings of three studies related to neonatal neuroprotection. The first study explores the potential use of haptoglobin as a treatment for cerebral intraventricular hemorrhage in preterm infants. The second study examines the impact of anakinra on immune function in infants with neonatal encephalopathy. The third study explores the therapeutic potential of human mesenchymal stem cells in encephalopathy of prematurity. These studies provide insights into potential treatments for neurodevelopmental impairments in preterm infants. Another study evaluates the impact of telemedicine consults on the time it takes to assess neonatal encephalopathy in a rural state, finding that the program significantly reduced assessment time and improved collaboration and communication. A study on infants with hypoxic-ischemic encephalopathy investigates the levels of immune regulatory cells and suggests their potential use as an adjuvant strategy to reduce inflammation. Lastly, a study compares the use of morphine in neonates undergoing therapeutic hypothermia for hypoxic-ischemic encephalopathy using two different cooling devices, finding no significant difference in morphine use between the groups. These studies highlight the need for further research and interventions to improve outcomes for infants with neonatal encephalopathy and hypoxic-ischemic encephalopathy. [Extracted from the article]